HAWTHORNE, N.Y.--(BUSINESS WIRE)--March 15, 2006--Taro Pharmaceutical Industries Ltd. (“Taro,” Nasdaq: TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. (“Taro USA”), its U.S. affiliate, has received final approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Mometasone Furoate Topical Solution USP, 0.1% (Lotion) (“mometasone lotion”).
